Phase
Condition
Chest Pain
Congestive Heart Failure
Heart Failure
Treatment
Sotagliflozin
Placebo
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: patients should meet all of the following criteria
Ambulatory patients age ≥ 18 years
Written informed consent prior to admission to the trial.
No diabetes as confirmed by HbA1c <6.5%, fasting serum glucose <126 mg/dL, andreview of concomitant medications and medical history
Diagnosis of Heart failure (NYHA II to III)
LVEF > 50%
On medical therapy for heart failure consistent with prevailing cardiovascularguidelines at a stable dose for ≥4 weeks prior to screening, except for diureticswhich must have been stable for ≥2 weeks prior to screening
Women of child-bearing potential must agree to use birth control measures with afailure rate of <1% per year during the treatment period of the study
Exclusion
Exclusion Criteria:
Type 1 and Type 2 diabetes
Acute coronary syndrome (ACS) or cardiac surgery within the last week.
Pregnant or lactating women,
Acute decompensated HF or hospitalized for HF within 1 month from screening visit
Glomerular Filtration Rate (GFR) < 25 ml/ min/1.73m2,
Patients on drugs with potential interaction with sotagliflozin including digoxin,phenytoin, HIV medication and rifampin.
Receiving SGLT2-I 3-months prior to randomization.
non-MRI compatible PM or ICD and any other medical or physical condition consideredunappropriated by a study physician.
Study Design
Connect with a study center
Icahn School of Medicine at Mount Sinai
New York, New York 10029
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.